BRAF V600E mutation has been observed in one third of rhabdoid meningiomas (6), which have poor prognosis, and could be useful in the identification of these aggressive tumor subtypes as well as for the stratification of patients eligible for tentative treatment with BRAF inhibitors such as vemurafenib or dabrafenib (5). The gene discussed is BRAF; the disease is Rhabdoid Meningioma.